Lineage Cell Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 12, 2025
LCTX$1.08+5.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporation by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description | ExhibitNumber | Filing | Filing Date | File No. |
| 3.1 | Restated Articles of Incorporation, as amended | 3.1 | 10-Q | November 9, 2023 | 001-12830 |
| 3.2 | Certificate of Ownership | 3.1 | 8-K | August 12, 2019 | 001-12830 |
| 3.3 | Second Amended and Restated Bylaws | 3.1(a) | 8-K | June 13, 2024 | 001-12830 |
| 10.1^ | Amendment No. 2 to the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan | 10.1 | 8-K | July 2, 2025 | 001-12830 |
| 31.1* | Certification of Chief Executive Officer pursuant to Form of Rule 13a-14(a), as Adopted Pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002 | ||||
| 31.2* | Certification of Chief Financial Officer pursuant to Form of Rule 13a-14(a), as Adopted Pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002 | ||||
| 32.1# | Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | ||||
| 101.INS* | XBRL Instance Document - the instance document does not appear in the Interactive Data as its XBRL tags are embedded within the Inline XBRL document | ||||
| 101.SCH* | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase documents | ||||
| 104* | Cover page formatted as Inline XBRL and contained in Exhibit 101 | ||||
- Filed herewith
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.